Get the Stockscreener App
1,117.26
0.92%
10.18
Pre-market:
1115.71
-1.55
-0.14%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,117.26, with a volume of 2.90M.
It is up +0.92% in the last 24 hours and up +4.91% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,107.08
Open:
$1129.41
24h Volume:
2.90M
Relative Volume:
0.91
Market Cap:
$996.31B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
40.22
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+0.47%
1M Performance:
+4.91%
6M Performance:
+3.74%
1Y Performance:
+43.59%
1-Day Range:
$1,100.98
$1,135.14
1-Week Range:
$1,079.22
$1,135.14
52-Week Range:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,117.26 | 987.23B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
241.00 | 575.52B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
234.89 | 414.77B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.60 | 295.39B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.12 | 292.66B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors - Insider Monkey
Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration - Forbes
Lilly’s GLP-1 windfall fuels M&A ‘land grab’ across 10 deals, $25B - BioWorld News
Lilly taps Abbisko for $1.9B discovery deal - BioWorld News
Index Ventures entities exit Centessa (CNTA) stake as Eli Lilly acquisition closes - Stock Titan
Centessa (CNTA) sale to Eli Lilly at $38 plus CVR detailed in Form 4 - Stock Titan
Eli Lilly dives into hair loss treatments with investment in AI startup Absci - statnews.com
Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI) - Seeking Alpha
White House bats down speculation that Trump got access to Eli Lilly obesity drug - NewsNation
Portland-area biotech receives $100M investment led by Eli Lilly - The Business Journals
Lilly Completes Centessa Acquisition to Expand Sleep Disorder Drug Pipeline - citybiz
At BIO, a glimpse behind Lilly and Chai’s partnership - statnews.com
Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Benzinga
Lilly Expands AI Drug Discovery Push With ‘App Store’ Model For Biotech Scientists - Pulse 2.0
Eli Lilly (NYSE:LLY): What Does The Abbisko Deal Mean? - Kalkine Media
Abbisko Therapeutics, Lilly Expand R&D Alliance - Contract Pharma
LLY or PFE: Which Drugmaker Offers the Stronger Growth Story? - The Globe and Mail
Eli Lilly and Abbisko Announce Drug Development Collaboration - Pharmaceutical Executive
Is Eli Lilly and Company (LLY) Strengthening Its Pain Management Strategy With New Biotech Acquisition? - Insider Monkey
NYSE Content Update: Abridge Partners with Eli Lilly, Nvidia to Improve Healthcare - 巴士的報
Lilly closes Centessa deal to pursue narcolepsy and sleep-wake drugs - Stock Titan
Abbisko Therapeutics Partners with Eli Lilly (LLY) for $1.9B R&D Collaboration - GuruFocus
Eli Lilly reunites with Abbisko in $1.9B, multitarget R&D pact - Fierce Biotech
White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President' - Benzinga
Eli Lilly suspends access to drug discounts for some hospitals - WTHR
Eli Lilly (LLY) Invests in AI Drug Development Amid Patent Expirations - GuruFocus
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says - Reuters
Abbisko Therapeutics enters potential US$1.9 billion R&D deal with Eli Lilly - The Standard (HK)
Who got experimental Eli Lilly obesity drug? Not Trump, White House says - Yahoo News UK
Abbisko Therapeutics Deepens R&D Collaboration with Lilly - PR Newswire
Is Trump on an Experimental Weight Loss Drug? An Investigation. - New York Magazine
Trump lauds Eli Lilly’s $3.5B venture in Lehigh Valley, Pa. workforce in Mack Trucks speech - Yahoo
Fact check: Who did Eli Lilly give access to its obesity drug? White House says not Trump - Yahoo
Zealthy Expands Insurance Coordination for GLP-1 Weight-Loss Medications - GlobeNewswire Inc.
White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April - The Independent
UBS offers autocallable notes linked to Eli Lilly (due 2029) | AMUB Prospectus Summary - Stock Titan
UBS (AMUB) launches autocallable notes tied to Eli Lilly stock, trade June 23 - Stock Titan
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America - Insider Monkey
Eli Lilly (NYSE:LLY) Fuels Weight-Care Buzz - Kalkine Media
Eli Lilly (LLY) Plans European Launch of Weight-Loss Pill by 202 - GuruFocus
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle - Benzinga
Eli Lilly and Bayer hit out at Germany’s spending on new medicines - Financial Times
Eli Lilly Chose One 79-Year-Old for Retatrutide While Millions Rely on Gray Market - Tech Times
Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe - Reuters
Eli Lilly plans European weight-loss pill launch by early 2027 - Investing.com
Illumina Appoints Eli Lilly R&D Leader Daniel Skovronsky to Board of Directors - citybiz
Eli Lilly Approved Obesity Drug for Mystery 79-Year-Old Patient - The New Republic
Illumina adds Eli Lilly executive to board of directors - Investing.com
Sangamo Therapeutics files for bankruptcy after unique 30-year run - The Business Journals
Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program - statnews.com
Sangamo files for Chapter 11, signs asset sale deals with Lilly - Investing.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):